Caroline Mary

A dynamic and dedicated engineer since the company’s inception, Caroline has built a career spanning over 19 years at OSE Immunotherapeutics.

She began her career in 2006 at TclPharma / Effimune as the company’s first employee. She contributed to the engineering and development of the company’s first molecule, FR104 (licensed to Veloxis). Over the years, Caroline has developed and structured OSE Immunotherapeutics’ Antibody Discovery & Engineering team. Together with her team, she has led numerous research and preclinical development programs, including: Lusvertikimab (positive results in ulcerative colitis), BI770371 (licensed to Boehringer), OSE-279 (currently in Phase 1b clinical development), and ABBV-230 (licensed to AbbVie).

Today, as Head of the Research Laboratory, Caroline leads the Antibody Discovery & Engineering team in close collaboration with all departments of the company, with the aim of identifying and developing innovative therapeutic approaches.

In addition to her scientific responsibilities, she is actively involved in the company’s life: a member of the Social and Economic Committee (CSE) since 2020.

Caroline holds a master’s degree in biology.